New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago
Background A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2022-03-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/8/1/00577-2021.full |
| _version_ | 1811297735309000704 |
|---|---|
| author | Malvika Kaul Preeti Gupta Salil Kalra Jessica Gardner Howard S. Gordon Israel Rubinstein |
| author_facet | Malvika Kaul Preeti Gupta Salil Kalra Jessica Gardner Howard S. Gordon Israel Rubinstein |
| author_sort | Malvika Kaul |
| collection | DOAJ |
| description | Background
A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue.
Methods
In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months.
Results
We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%).
Conclusions
Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies. |
| first_indexed | 2024-04-13T06:08:38Z |
| format | Article |
| id | doaj.art-2aed66f4efce4d8b8b415abfdca117df |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-04-13T06:08:38Z |
| publishDate | 2022-03-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-2aed66f4efce4d8b8b415abfdca117df2022-12-22T02:59:08ZengEuropean Respiratory SocietyERJ Open Research2312-05412022-03-018110.1183/23120541.00577-202100577-2021New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan ChicagoMalvika Kaul0Preeti Gupta1Salil Kalra2Jessica Gardner3Howard S. Gordon4Israel Rubinstein5 Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA Research Services, Jesse Brown VA Medical Center Chicago, Chicago, IL, USA Medical Services, Jesse Brown VA Medical Center Chicago, Chicago, IL, USA Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA Background A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue. Methods In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months. Results We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%). Conclusions Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies.http://openres.ersjournals.com/content/8/1/00577-2021.full |
| spellingShingle | Malvika Kaul Preeti Gupta Salil Kalra Jessica Gardner Howard S. Gordon Israel Rubinstein New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago ERJ Open Research |
| title | New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago |
| title_full | New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago |
| title_fullStr | New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago |
| title_full_unstemmed | New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago |
| title_short | New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago |
| title_sort | new domiciliary supplemental oxygen therapy after hospitalisation for covid 19 in metropolitan chicago |
| url | http://openres.ersjournals.com/content/8/1/00577-2021.full |
| work_keys_str_mv | AT malvikakaul newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago AT preetigupta newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago AT salilkalra newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago AT jessicagardner newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago AT howardsgordon newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago AT israelrubinstein newdomiciliarysupplementaloxygentherapyafterhospitalisationforcovid19inmetropolitanchicago |